Sarepta Drops Envision Gene Therapy Study After Year On Hold, Calling Restart Impractical

Sarepta will not resume the paused Envision trial; a liver-safety cohort now carries its plan for non-ambulatory Duchenne patients.

Share
Sarepta Drops Envision Gene Therapy Study After Year On Hold, Calling Restart Impractical

Sarepta Therapeutics, which develops RNA-targeted and gene therapies for rare diseases, will not restart the Envision study of its Duchenne gene therapy Elevidys, Louise Rodino-Klapac, its president of research and development and technical operations, said on the company's third-quarter earnings call Thursday. The trial has been on hold for over a year, and the company said guidance for 2026 net product revenue now starts $50 million higher.

Why Envision is finished

Rodino-Klapac said Sarepta decided "not to resume enrollment of the Envision study." About half of its intended sample size had been recruited. Restarting after so long a pause, she said, brings operational and technical barriers the company does not believe are practical to overcome.

She said the company's commitment to non-ambulatory Duchenne patients "remains steadfast," and that the population has fewer treatment options.

Asked by an Oppenheimer analyst how the move affects Elevidys's return for those patients, CEO Mike Severino said Envision "was not part of our plan to return to the non-ambulatory population." He said it would not have produced data in time to inform that decision, and called the choice purely practical.

Cohort 8 carries the plan

Severino said Endeavor Cohort 8, which tests prophylactic sirolimus around Elevidys infusion, is the central piece of the path back. Rodino-Klapac said the data will show whether the drug can reduce acute liver injury, a known risk of the gene therapy. Enrollment should finish by the end of this year.

Sarepta plans to approach the FDA toward the end of the first quarter, once 12-week safety data from Cohort 8 are in hand. Rodino-Klapac described the engagement as set for the first quarter of 2027.

Guidance up, Elevidys stabilizing

Chief Commercial Officer Patrick Moss said third-quarter net product revenue was about $324 million, including $83 million from Elevidys and $240 million from the exon-skipping franchise. Chief Financial Officer Ryan Wong said product revenue fell 13% from a year earlier, driven by lower Elevidys sales. The raised guidance range is $1.25 billion to $1.3 billion.

Severino, who said he joined about 90 days ago, said Elevidys enrollment-form activity matched the second quarter and sets a new baseline for judging commercial initiatives. Moss said more than 1,500 patients have now been treated with Elevidys.

Wong said Sarepta also narrowed full-year non-GAAP R&D and administrative spending guidance to $800 million to $825 million. Multiple-dose data for its DM1 and FSHD programs are expected in the coming weeks.

Sarepta's next marker on non-ambulatory patients is the FDA approach toward the end of the first quarter, with Cohort 8 safety data in hand.

Sources